AI English summary of an SEC filing — figures as filed
Alexandria Real Estate Equities AREThe company said the board elected Claire Aldridge, Ph.D., as a director on February 28, 2025, effective March 14, 2025. As a result, it increased the size of the board from 8 to 9 directors.
Key points
AI summaryThe company said the board elected Claire Aldridge, Ph.D., as a director on February 28, 2025, effective March 14, 2025. As a result, it increased the size of the board from 8 to 9 directors.
The company said it appointed Dr. Aldridge to its Life Science Committee. It determined she is independent under New York Stock Exchange listing standards and Securities and Exchange Commission rules. It also said her term runs until the 2025 annual meeting of stockholders.
The company said Dr. Aldridge served as Chief Strategy Officer of Form Bio, Inc. from July 2022 to August 2024, where she led the integration of AI and machine learning into genomic analysis and advanced therapeutics programs such as gene therapy. It also said she has more than 25 years of experience helping turn scientific discoveries into patient and commercial benefits.
The company said Dr. Aldridge will receive 1,000 shares of restricted stock under the Amended and Restated 1997 Stock Award and Incentive Plan upon her initial election to the board. The shares will vest in full on the 2nd anniversary of the grant date. She will also generally participate in the compensation arrangements for the company's independent directors.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Director Election and Board Expansion
The company said the board elected Claire Aldridge, Ph.D., as a director on February 28, 2025, effective March 14, 2025. As a result, it increased the size of the board from 8 to 9 directors.
Source · Based on the filing body and exhibits
Committee Assignment and Independence Determination
The company said it appointed Dr. Aldridge to its Life Science Committee. It determined she is independent under New York Stock Exchange listing standards and Securities and Exchange Commission rules. It also said her term runs until the 2025 annual meeting of stockholders.
Source · Based on the filing body and exhibits
Background of the New Director
The company said Dr. Aldridge served as Chief Strategy Officer of Form Bio, Inc. from July 2022 to August 2024, where she led the integration of AI and machine learning into genomic analysis and advanced therapeutics programs such as gene therapy. It also said she has more than 25 years of experience helping turn scientific discoveries into patient and commercial benefits.
Source · Based on the filing body and exhibits
Director Compensation Terms
The company said Dr. Aldridge will receive 1,000 shares of restricted stock under the Amended and Restated 1997 Stock Award and Incentive Plan upon her initial election to the board. The shares will vest in full on the 2nd anniversary of the grant date. She will also generally participate in the compensation arrangements for the company's independent directors.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…